Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Immuno-oncology has significant diagnostic needs including identifying patients most likely to respond to therapies. Current diagnostic approaches often fall short, due in large part to the complexity of the biology driving therapy responsiveness. As such, the biopharma industry is exploring many emerging approaches covering tumor, immune and even microbiome-related pathways and biomarkers.
Latest From Innovation
Will Advanced Technology Simulations Lead To More And Better Drugs? Start-Up Schrodinger Says It Can
Schrodinger LLC is a leading player in the emerging high-stakes field of computational chemical simulation software to boost the quality and productivity of drug discovery and lead generation. Its business model relies heavily on validating theoretical concepts of science and engineering in real-world settings through partnerships with a blue-chip list of pharma and biotech companies.
While digital health applications represent a major opportunity for biopharma, acting on the premise – and realizing its promise – depends on quantum-level shifts in organizational design and cultural resilience to disruptive change. In an In Vivo interview, Omnicom Health Group’s SVP for Data Solutions Christina Kim says industry progress toward a digitized future varies, but the necessity to act is clear.
Keeping the patient at the center is just as important in the development of high-risk innovations that serve unmet needs as it is for all other medtech solutions. That is the view of Pixium Vision CEO Khalid Ishaque, whose company is on the cusp of taking many dry-AMD sufferers out of blindness with artificial bionic vision technology. It recently performed the first successful human implantation and activation of its Prima implant.
Execs from Merck, Pfizer, Bristol, Abbvie and smaller biopharmas weigh in on how developments in cancer research may benefit other disease areas, especially autoimmune and neurological conditions.
The health care industry has come a long way in the past 35 years, although in some areas very little has changed. Recently retired In Vivo editor Peter Charlish has seen most of the major developments, and in his final feature, he looks back at some of the big stories in a reporting career that began in the early 1980s.
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.